KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Operating Leases (2018 - 2025)

Historic Operating Leases for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $677.0 million.

  • Moderna's Operating Leases fell 328.57% to $677.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $677.0 million, marking a year-over-year decrease of 328.57%. This contributed to the annual value of $671.0 million for FY2024, which is 435.46% up from last year.
  • Latest data reveals that Moderna reported Operating Leases of $677.0 million as of Q3 2025, which was down 328.57% from $682.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Operating Leases registered a high of $730.0 million during Q3 2023, and its lowest value of $92.0 million during Q4 2022.
  • In the last 5 years, Moderna's Operating Leases had a median value of $141.0 million in 2022 and averaged $385.6 million.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 1320.75% in 2022, then surged by 59891.3% in 2023.
  • Over the past 5 years, Moderna's Operating Leases (Quarter) stood at $106.0 million in 2021, then fell by 13.21% to $92.0 million in 2022, then soared by 598.91% to $643.0 million in 2023, then increased by 4.35% to $671.0 million in 2024, then grew by 0.89% to $677.0 million in 2025.
  • Its last three reported values are $677.0 million in Q3 2025, $682.0 million for Q2 2025, and $682.0 million during Q1 2025.